Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FLAG Clear all
Completed Not applicable Interventional Results available

Does Framing and Humor Improve the Effectiveness of Messages About COVID-19 Vaccine

NCT05085613
View directory record Official record
Conditions
Beliefs
Interventions
Corrective message framing and humor
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
21 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 17, 2026, 10:10 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

NCT07604233
View directory record Official record
Conditions
Myeloid Leukemia
Interventions
Fludarabine, Cytarabine, Idarubicin, Filgrastim, Venetoclax, Asciminib, Blinatumomab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia

NCT00003619
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Thrombocytopenia
Interventions
filgrastim, vitamin E, busulfan, cytarabine, etoposide, fludarabine phosphate, isotretinoin, topotecan hydrochloride, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Dietary Supplement · Drug + 1 more
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
19 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 17, 2026, 10:10 PM EDT
Recruiting Phase 2 Interventional

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

NCT07046078
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Fludarabine, Idarubicin, Multigated Acquisition Scan, Peripheral Blood Stem Cell, Questionnaire Administration, Recombinant Granulocyte Colony-Stimulating Factor, Total-Body Irradiation
Procedure · Drug · Biological + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 17, 2026, 10:10 PM EDT
Recruiting Phase 1 Interventional

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06001788
View directory record Official record
Conditions
AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
Interventions
Ziftomenib, Fludarabine, Idarubicin, Cytarabine, Gilteritinib, Granulocyte colony-stimulating factor
Drug · Biological
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
38
States / cities
Gilbert, Arizona • Los Angeles, California • Orange, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02642965
View directory record Official record
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
Cytarabine, Filgrastim, Fludarabine Phosphate, Laboratory Biomarker Analysis, Liposome-encapsulated Daunorubicin-Cytarabine, Pharmacological Study
Drug · Biological · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 17, 2026, 10:10 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

NCT06928662
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Acute Undifferentiated Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Acute Undifferentiated Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Interventions
Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Cytarabine, Echocardiography Test, Filgrastim, Fludarabine, Hematopoietic Cell Transplantation, Idarubicin, Multigated Acquisition Scan, Pheresis, Total-Body Irradiation, Biospecimen Collection
Drug · Procedure · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 17, 2026, 10:10 PM EDT
Terminated Phase 2 Interventional

A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia

NCT05780879
View directory record Official record
Conditions
Secondary Acute Myeloid Leukemia
Interventions
Venetoclax, FLAG or CLAG Protocol
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 17, 2026, 10:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT04240002
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
Interventions
gilteritinib, fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF)
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
6 Months to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

NCT03068819
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
CIML NK Cell Infusion, CD3+ T Cell Product Infusion, Leukapheresis
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Not applicable Interventional Results available

An Emergency Department-To-Home Intervention to Improve Quality of Life and Reduce Hospital Use

NCT02079987
View directory record Official record
Conditions
ED Patients With Chronic Medical Illnesses
Interventions
ED-to-home care transition intervention, Usual Care
Behavioral · Other
Lead sponsor
University of Florida
Other
Eligibility
60 Years and older
Enrollment
1,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Feasibility Study of Delivering Adolescent Nutrition Interventions Through School-Based Platforms in Ethiopia

NCT04121559
View directory record Official record
Conditions
Dietary Diversity
Interventions
School Interventions, Community Interventions, School System Interventions
Behavioral
Lead sponsor
International Food Policy Research Institute
Other
Eligibility
10 Years to 14 Years · Female only
Enrollment
1,712 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

NCT02400281
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Crenolanib besylate, Idarubicin, Cytarabine, Azacytidine, Mitoxantrone, Etoposide, Fludarabine, G-CSF
Drug
Lead sponsor
Arog Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 17, 2026, 10:10 PM EDT
Active, not recruiting Not applicable Interventional

Machine-Learning Prediction and Reducing Overdoses With EHR Nudges

NCT06806163
View directory record Official record
Conditions
Opioid Overdose, Opioid Use, Opioid Use Disorder, Opioids
Interventions
EHR-Embedded Elevated-Risk Flag, EHR-Embedded Elevated-Risk Flag with Behavioral Nudges, Usual Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 10:10 PM EDT
Completed No phase listed Observational

Electronic Medical Record-Based Nudge to Reduce SLNB

NCT06006910
View directory record Official record
Conditions
Breast Cancer, Estrogen-receptor-positive Breast Cancer
Interventions
Column-based nudge in the EHR, No column-based nudge in the EHR
Behavioral
Lead sponsor
University of Pittsburgh Medical Center
Other
Eligibility
70 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Not applicable Interventional

Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition

NCT05721326
View directory record Official record
Conditions
Genetic Predisposition to Disease, Breast Cancer Female, Ovarian Cancer, Hereditary Breast and Ovarian Cancer, Hereditary Cancer Syndrome, Hereditary Diseases, Gene Mutation-Related Cancer
Interventions
Sequential EHR Communications
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
25 Years to 100 Years · Female only
Enrollment
1,283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 3 Interventional

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

NCT03250338
View directory record Official record
Conditions
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Interventions
Crenolanib, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF
Drug
Lead sponsor
Arog Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Sacramento, California • Gainesville, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 17, 2026, 10:10 PM EDT
Enrolling by invitation No phase listed Observational

CHAMP App Cardiac Study and Repository

NCT06034392
View directory record Official record
Conditions
Heart Defects, Congenital, Pediatrics
Interventions
CHAMP App
Device
Lead sponsor
Lori Erickson
Other
Eligibility
Up to 18 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Miami, Florida • New Orleans, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Results available

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

NCT02039726
View directory record Official record
Conditions
AML
Interventions
Quizartinib, Salvage Chemotherapy
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
36
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Not applicable Interventional Results available

Spouse READI (Resilience Education And Deployment Information) Post Deployment Telephone Support Groups

NCT01121250
View directory record Official record
Conditions
Spouses, Military Personnel, Coping Skills
Interventions
Telephone Discussion Groups, Education sessions
Behavioral
Lead sponsor
Memphis VA Medical Center
Federal
Eligibility
Female only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Not applicable Interventional

Group Digital Gaming: Experiences of Older Adults Living With Dementia in an Activity for Cognitive Impairment

NCT07541144
View directory record Official record
Conditions
Dementia
Interventions
Group-Based Digital Gaming
Behavioral
Lead sponsor
George Mason University
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Empowering Hispanic Patients' Lung Cancer Screening Uptake (Empower Latinx)

NCT06225414
View directory record Official record
Conditions
Lung Cancer
Interventions
Usual Care, Brief Patient Education, Patient education, Referral to financial navigation resources, Patient Reminders, Provider Reminders
Other · Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
10
States / cities
Anaheim, California • Costa Mesa, California • Irvine, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Not applicable Interventional Results available

Biocontainment Device for Aerosol Generating Procedures

NCT04532112
View directory record Official record
Conditions
Protective Device (Physical Object), Aerosol Disease, Droplet Spread
Interventions
Biocontainment Device For Aerosol Generating Procedures (Biobox), Control for aerosol generating procedures
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 17, 2026, 10:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Patient-Centered Reproductive Decision Support Tool for Women Veterans

NCT04584294
View directory record Official record
Conditions
Contraception, Contraception Behavior, Prepregnancy Health, Reproductive Health
Interventions
MyPath Web-Based Informational and Decision Support Tool
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 44 Years · Female only
Enrollment
465 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
12
States / cities
San Diego, California • Aurora, Colorado • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 17, 2026, 10:10 PM EDT